It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

As cell therapies scale, developers face a choice: redesign processes for all-in-one systems or manage complex bespoke ...

Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...

Despite the perception of biopharma as a field that is slow to adopt new technology, artificial intelligence (AI) has been quietly improving the sector for years, from candidate prioritization in drug ...

Cellares' $257 million funding supports the shift to an IDMO model, addressing cell therapy production challenges of capacity, cost, and consistency. The automated smart factory model, using Cell ...